Europe’s largest pharmaceutical firm reported first-quarter earnings that exceeded analysts’ expectations, but lowered its full-year guidance. Novo Nordisk now forecasts 2025 sales growth between 13% and 21%, and operating profit growth between 16% and 24% at constant exchange rates (CER), down 3 and 5 percentage points respectively from previous projections.
“We have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US. We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1 treatments,” chief executive, Lars Fruergaard Jørgensen, said.
